Lithium: A therapeutic option in Alzheimer’s disease and its prodromal stages?

@article{Haussmann2021LithiumAT,  title={Lithium: A therapeutic option in Alzheimer’s disease and its prodromal stages?},  author={Robert Haussmann and Felix Noppes and Moritz D. Brandt and Michael Bauer and Markus Donix},  journal={Neuroscience Letters},  year={2021},  volume={760},  url={https://api.semanticscholar.org/CorpusID:235385875}}

27 Citations

Molecular mechanisms and therapeutic potential of lithium in Alzheimer’s disease: repurposing an old class of drugs

Lithium’s mechanism of action in treating AD is focused on, highlighting the latest advances in preclinical studies and clinical trials, and the side effects of lithium therapy and coping strategies are explored, offering a potential therapeutic strategy for patients with AD.

Lithium Therapy’s Potential to Lower Dementia Risk and the Prevalence of Alzheimer’s Disease: A Meta-Analysis

The duration of treatment and the usage of lithium therapy seem to lower the risk of AD and postpone the onset of dementia.

Current and future therapeutic strategies for Alzheimer’s disease: an overview of drug development bottlenecks

A literature review of the possible pathophysiological mechanisms underlying the occurrence and development of AD, focusing on anti-Aβ and anti-tau drugs, mitochondria-targeting and multi-targets, commercially available drugs, bottlenecks encountered in drug development, and the possible targets and therapeutic strategies for future drug development.

The Potential of a Stratified Approach to Drug Repurposing in Alzheimer’s Disease

Novel, stratified drug repurposing studies may expedite the discovery of alternative, effective, and more affordable treatment options for a rapidly expanding patient population in comparison with traditional drug development methods in AD.

Lithium Enhances Hippocampal Glucose Metabolism in an In Vitro Mice Model of Alzheimer’s Disease

The results showed that lithium significantly stimulates glucose uptake and replenishes ATP levels by preferential oxidation of glucose through glycolysis in neurons from WT mice, and can act as a potential therapeutic agent in AD.

Microdose lithium improves behavioral deficits and modulates molecular mechanisms of memory formation in female SAMP-8, a mouse model of accelerated aging

This work shows that lithium effects in neuroprotection along the aging process are not related to a unique cellular mechanism but produce multiple effects that slowly protect the brain along the aging process.

Low-Dose Lithium Supplementation Influences GSK3β Activity in a Brain Region Specific Manner in C57BL6 Male Mice

Evidence is provided for low-dose lithium supplementation to inhibit GSK3 activity in the brain of an early, diet-induced Alzheimer’s disease model and indicates that GSK3 activity can be inhibited despite any changes in phosphorylation.

The role of PI3K signaling pathway in Alzheimer’s disease

Despite the challenges and hurdles, cumulative findings of novel targets and agents in the PI3K/Akt signaling axis are expected to hold promise for advancing AD prevention and treatment.

40 References

Does Lithium Prevent Alzheimer’s Disease?

Lithium treatment may yield disease-modifying effects in AD, both by the specific modification of its pathophysiology via inhibition of overactive GSK3B, and by the unspecific provision of neurotrophic and neuroprotective support.

Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease.

The efficacy of a microdose lithium treatment in preventing cognitive loss is suggested, reinforcing its therapeutic potential to treat AD using very low doses.

Neuroprotective effects of lithium: implications for the treatment of Alzheimer's disease and related neurodegenerative disorders.

The neurobiological properties of lithium are revisited in light of the available evidence of its neurotrophic and neuroprotective properties, and the rationale for its use in the treatment and prevention of neurodegenerative diseases is discussed.

Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: randomised clinical trial

Long-term lithium attenuates cognitive and functional decline in amnestic mild cognitive impairment, and modifies Alzheimer's disease-related CSF biomarkers, which reinforces the disease-modifying properties of lithium in the MCI–Alzheimer's disease continuum.

Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.

The notion that lithium treatment may lead to reduced hyperphosphorylation of tau protein after a short 10-week treatment in the Alzheimer's disease target population is not supported.

Lithium as a Treatment for Alzheimer’s Disease: A Systematic Review and Meta-Analysis

Lithium treatment may have beneficial effects on cognitive performance in subjects with MCI and AD dementia, and the results indicate that lithium treatment may have beneficial effects on cognitive performance in subjects with MCI.

Increase of BDNF Serum Concentration in Lithium Treated Patients with Early Alzheimer's Disease

In AD patients treated with lithium, a significant increase of BDNF serum levels, and additionally a significant decrease of ADAS-Cog sum scores in comparison to placebo-treated patients, were found.

Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial

The notion that lithium has disease-modifying properties with potential clinical implications in the prevention of Alzheimer's disease is supported.

Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder

The case-control data suggest that lithium treatment reduced the prevalence of Alzheimer's disease in patients with bipolar disorder to levels in the general elderly population, in accordance with reports that lithium inhibits crucial processes in the pathogenesis of Alzheimer’s disease.

Drug-induced cerebral glucose metabolism resembling Alzheimer’s Disease: a case study

Pharmacological treatment of older subjects may mimic glucose metabolism and clinical symptoms of Alzheimer's disease, and amyloid PET is a helpful tool to additionally rule out underlying Alzheimer’s disease in situations of clinical doubt.

Related Papers

Showing 1 through 3 of 0 Related Papers